Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial-Reference-Cited by-同舟云学术

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Published:2019-06 Issue:6 Volume:6 Page:e355-e363
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Wohl David A,Yazdanpanah Yazdan,Baumgarten Axel,Clarke Amanda,Thompson Melanie A,Brinson Cynthia,Hagins Debbie,Ramgopal Moti N,Antinori Andrea,Wei Xuelian,Acosta Rima,Collins Sean E,Brainard Diana,Martin Hal

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference22 articles.

1. EACS treatment guidelines, version 9.1 updated,2018

2. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV,2018

3. antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA panel;Günthard;JAMA,2016

4. Triumeq (dolutegravir/abacavir/lamibudie) summary of product characteristics,2018

5. Bictarvy (bictegravir/emtricitabine/tenofovir alafenamide) summary of product characteristics,2018

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review;2024-01-07

2. Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania;Scientific Reports;2024-01-05

3. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters;International Journal of Antimicrobial Agents;2024-01

4. Current antiretroviral therapy: A review;Terapevticheskii arkhiv;2023-12-28

5. Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts;HIV Medicine;2023-12-26